Published in Proc Natl Acad Sci U S A on July 25, 2007
Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS One (2012) 1.60
Nucleotide bias observed with a short SELEX RNA aptamer library. Nucleic Acid Ther (2011) 1.15
Interleukin-1β modulates smooth muscle cell phenotype to a distinct inflammatory state relative to PDGF-DD via NF-κB-dependent mechanisms. Physiol Genomics (2012) 1.04
E2F3 plays an essential role in cardiac development and function. Cell Cycle (2008) 0.94
Identification of RNA aptamers that internalize into HPV-16 E6/E7 transformed tonsillar epithelial cells. Virology (2013) 0.86
Role of E2F1-cyclin E1-cyclin E2 circuit in human coronary smooth muscle cell proliferation and therapeutic potential of its downregulation by siRNAs. Mol Med (2009) 0.81
Contrasting roles of E2F2 and E2F3 in cardiac neovascularization. PLoS One (2013) 0.78
Vein graft neointimal hyperplasia is exacerbated by CXCR4 signaling in vein graft-extrinsic cells. J Vasc Surg (2012) 0.77
Contrasting roles of E2F2 and E2F3 in endothelial cell growth and ischemic angiogenesis. J Mol Cell Cardiol (2013) 0.77
Method for Confirming Cytoplasmic Delivery of RNA Aptamers. Methods Mol Biol (2016) 0.76
In vitro RNA SELEX for the generation of chemically-optimized therapeutic RNA drugs. Methods (2016) 0.75
Current siRNA targets in the prevention and treatment of intimal hyperplasia. Discov Med (2014) 0.75
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 35.96
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
The regulation of E2F by pRB-family proteins. Genes Dev (1998) 12.77
Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol (2002) 7.64
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest (1983) 6.05
Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A (1997) 5.83
The E2F transcriptional network: old acquaintances with new faces. Oncogene (2005) 4.87
Chemokines in the pathogenesis of vascular disease. Circ Res (2004) 4.64
Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ (1998) 4.38
The E2F1-3 transcription factors are essential for cellular proliferation. Nature (2001) 4.37
Aptamers: an emerging class of therapeutics. Annu Rev Med (2005) 4.15
Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation (1998) 3.92
E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev (1998) 3.48
The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc Natl Acad Sci U S A (2001) 2.65
E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. Mol Cell (2000) 2.48
Mouse model of arterial injury. Circ Res (1993) 2.45
E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes. EMBO J (2003) 2.14
Cloning and characterization of mouse E2F8, a novel mammalian E2F family member capable of blocking cellular proliferation. J Biol Chem (2005) 1.95
A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A (1995) 1.71
Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced by loss of Rb. Cell Growth Differ (2002) 1.51
Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol (2006) 1.41
Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure. Mol Pharmacol (2002) 1.38
Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today (2006) 1.32
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. Am Heart J (2005) 1.20
Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med (2006) 1.19
In vitro selection of nucleic acid aptamers that bind proteins. Methods Enzymol (1996) 1.18
Neointimal hyperplasia rapidly reaches steady state in a novel murine vein graft model. J Vasc Surg (2002) 1.10
Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res (1997) 1.07
Saphenous vein grafts: to use or not to use? Heart Lung Circ (2004) 1.06
Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis. Proc Natl Acad Sci U S A (1999) 1.06
Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A (1995) 1.05
Vein graft neointimal hyperplasia is exacerbated by tumor necrosis factor receptor-1 signaling in graft-intrinsic cells. Arterioscler Thromb Vasc Biol (2004) 1.00
Regulation of vascular smooth muscle growth by alpha 1-adrenoreceptor subtypes in vitro and in situ. J Biol Chem (1995) 0.98
Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure. Vasc Endovascular Surg (2005) 0.98
Stress and vascular responses: mitogen-activated protein kinases and activator protein-1 as promising therapeutic targets of vascular remodeling. J Pharmacol Sci (2003) 0.95
Towards the prevention of vein graft failure. Int J Cardiol (1997) 0.91
New targets for PPARgamma in the vessel wall: implications for restenosis. Int J Obes (Lond) (2005) 0.90
Expression of cell cycle regulators during smooth muscle cell proliferation after balloon catheter injury of rat artery. J Korean Med Sci (2004) 0.79
Structural and functional consequences of bypass grafting with autologous vein. Cryobiology (1994) 0.79
Opportunities for gene therapy in preventing vein graft failure after coronary artery bypass surgery. Diabetes Obes Metab (2006) 0.79
[Hyperplasia of the arterial intima due to smooth muscle cell proliferation. Current data, experimental treatments and perspectives]. J Mal Vasc (2003) 0.79
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Seven-transmembrane-spanning receptors and heart function. Nature (2002) 5.38
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
Aptamers: an emerging class of therapeutics. Annu Rev Med (2005) 4.15
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation (2002) 3.15
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res (2010) 3.00
A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
RNA aptamers as reversible antagonists of coagulation factor IXa. Nature (2002) 2.73
Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell (2007) 2.65
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med (2007) 2.48
Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med (2007) 2.38
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
In vivo activity of nuclease-resistant siRNAs. RNA (2004) 2.33
Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer (2006) 2.32
A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J (2005) 2.29
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22
G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res (2008) 2.22
Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol (2004) 2.18
Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation (2008) 2.17
Hyperphosphorylation of the cardiac ryanodine receptor at serine 2808 is not involved in cardiac dysfunction after myocardial infarction. Circ Res (2012) 2.16
Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol (2003) 2.08
Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res (2006) 2.08
Publication misconduct and plagiarism retractions: a systematic, retrospective study. Curr Med Res Opin (2012) 2.05
A global role for KLF1 in erythropoiesis revealed by ChIP-seq in primary erythroid cells. Genome Res (2010) 2.02
Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A (2008) 1.93
Development of universal antidotes to control aptamer activity. Nat Med (2009) 1.93
Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91
C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation (2012) 1.90
Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A (2003) 1.89
Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension (2013) 1.83
Gene therapy in heart failure. Circ Res (2008) 1.79
Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. Proc Natl Acad Sci U S A (2004) 1.76
Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor. Mol Cell Biol (2003) 1.76
Embracing the complexity of genomic data for personalized medicine. Genome Res (2006) 1.75
Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation (2006) 1.73
Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab (2012) 1.73
Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation (2007) 1.73
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res (2006) 1.72
Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem (2001) 1.70
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68
S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol (2011) 1.68
β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation. Circ Res (2012) 1.66
Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation (2006) 1.64
Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res (2013) 1.62
G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in black Americans. Hypertension (2009) 1.62
β-arrestin1-biased β1-adrenergic receptor signaling regulates microRNA processing. Circ Res (2013) 1.59
Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest (2004) 1.58
Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res (2005) 1.57
Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol (2006) 1.57
Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation (2008) 1.56
Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med (2011) 1.54
Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ Res (2010) 1.52
Cardiac G-protein-coupled receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant to adverse alterations and remodeling after myocardial infarction. Circulation (2012) 1.52
Direct evidence of intracrine angiotensin II signaling in neurons. Am J Physiol Cell Physiol (2014) 1.51
Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc Natl Acad Sci U S A (2002) 1.51
Downregulation of adiponectin induced by tumor necrosis factor α is involved in the aggravation of posttraumatic myocardial ischemia/reperfusion injury. Crit Care Med (2011) 1.50
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46
The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells. J Biol Chem (2003) 1.46
Retracted An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One (2008) 1.45
Gene expression signatures of radiation response are specific, durable and accurate in mice and humans. PLoS One (2008) 1.44
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43
Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem (2003) 1.43
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol (2008) 1.42